Single-target therapies have demonstrated only modest benefit in [Alzheimer's disease](/diseases/alzheimers-disease) — [Lecanemab](/entities/lecanemab) shows 27% slowing of cognitive decline[@vanDyck2023], while [Donanemab](/entities/donaneumab) demonstrates 35% slowing in a subset of patients[@Mintun2024]. This modest efficacy suggests that combination therapy targeting multiple mechanisms simultaneously may be necessary for meaningful disease modification. The rationale is grounded in AD's multifactorial pathogenesis: amyloid pathology, tau neurodegeneration, neuroinflammation, metabolic dysfunction, and vascular impairment all contribute concurrently[@Cummings2024].
Matrix Size: 15x15 (105 unique pairwise combinations). Each combination is scored across four dimensions: Mechanistic Synergy, Safety Compatibility, Delivery Compatibility, and Clinical Evidence (each 0-10, max 40).
AD is fundamentally a multi-pathology disease. Even the best anti-amyloid antibodies reduce amyloid burden by 60-70% but achieve only modest clinical benefit[@Sims2024]. This gap between biomarker reduction and clinical outcomes underscores the need to simultaneously address downstream mechanisms (tau, neuroinflammation, metabolic dysfunction) alongside upstream pathology removal.
Single-target therapies have demonstrated only modest benefit in [Alzheimer's disease](/diseases/alzheimers-disease) — [Lecanemab](/entities/lecanemab) shows 27% slowing of cognitive decline[@vanDyck2023], while [Donanemab](/entities/donaneumab) demonstrates 35% slowing in a subset of patients[@Mintun2024]. This modest efficacy suggests that combination therapy targeting multiple mechanisms simultaneously may be necessary for meaningful disease modification. The rationale is grounded in AD's multifactorial pathogenesis: amyloid pathology, tau neurodegeneration, neuroinflammation, metabolic dysfunction, and vascular impairment all contribute concurrently[@Cummings2024].
Matrix Size: 15x15 (105 unique pairwise combinations). Each combination is scored across four dimensions: Mechanistic Synergy, Safety Compatibility, Delivery Compatibility, and Clinical Evidence (each 0-10, max 40).
AD is fundamentally a multi-pathology disease. Even the best anti-amyloid antibodies reduce amyloid burden by 60-70% but achieve only modest clinical benefit[@Sims2024]. This gap between biomarker reduction and clinical outcomes underscores the need to simultaneously address downstream mechanisms (tau, neuroinflammation, metabolic dysfunction) alongside upstream pathology removal.
The rationale for combination therapy includes: (1) AD involves parallel pathological cascades that cannot be fully addressed by single-target interventions; (2) compensatory pathways may limit monotherapy efficacy; (3) sequential therapy (remove amyloid, then address tau/inflammation) may miss the therapeutic window for multi-modal intervention; (4) synergistic targeting of complementary mechanisms may produce more than additive effects[@Aisen2023][@Bassett2024].
| # | Approach | Score | Key Reference |
|---|----------|------:|---------------|
| 1 | Lifestyle interventions (exercise, diet, sleep, cognitive training) | 61 | FINGER trial[@Ngandu2015] |
| 2 | Anti-amyloid antibodies ([Lecanemab](/entities/lecanemab), [Donanemab](/entities/donaneumab)) | 55 |[@vanDyck2023][@Mintun2024] |
| 3 | GLP-1 agonists (Semaglutide, Dulaglutide) | 55 |[@Swanson2023][@Lee2024] |
| 4 | Anti-tau antibodies (E2814, Bepranemab) | 52 |[@McDade2024] |
| 5 | Anti-tau ASOs (BIIB080, MAPT-ASO) | 51 |[@Cummings2024] |
| 6 | Intranasal insulin (detemir, aspart) | 50 |[@Tariot2024] |
| 7 | [TREM2](/genes/trem2) agonists (AL002, AJ201) | 49 |[@Huang2024] |
| 8 | Focused ultrasound blood-brain barrier opening + drug delivery | 49 |[@Cummings2024] |
| 9 | Mitochondrial therapies (NAD+ boosters, urolithin A) | 47 |[@Hampel2024] |
| 10 | Anti-inflammatory (Masitinib, Sargramostim) | 46 |[@Cummings2024] |
| 11 | Senolytics (Dasatinib + Quercetin, Fisetin) | 45 |[@Blundell2024] |
| 12 | [HDAC](/entities/hdac-enzymes) inhibitors (Vorinostat, Romidepsin) | 41 |[@Hampel2024] |
| 13 | Sigma-1 agonists (Blarcamesine/Anavex 2-73) | 41 |[@Cummings2024] |
| 14 | Glutamate modulators (Troriluzole, Memantine) | 38 |[@Long2024] |
| 15 | Gene therapy (AAV-BDNF, AAV-NGF, AAV-APPsi) | 38 |[@Bateman2023] |
| | 1.Lifestyle | 2.Anti-Aβ Ab | 3.GLP-1 | 4.Anti-Tau Ab | 5.Anti-Tau ASO | 6.Intranasal Ins | 7.TREM2 Ag | 8.FUS | 9.Mito | 10.Anti-Infl | 11.Senolytic | 12.HDAC | 13.σ1 Ag | 14.Glutamate | 15.Gene Tx |
|---|:---:|:---:|:---:|:---:|:---:|:---:|:---:|:---:|:---:|:---:|:---:|:---:|:---:|:---:|:---:|
| 1.Lifestyle | -- | | | | | | | | | | | | | | |
| 2.Anti-Aβ Ab | 10/10/10/8=38 | -- | | | | | | | | | | | | | |
| 3.GLP-1 | 10/10/10/7=37 | 8/9/9/7=33 | -- | | | | | | | | | | | | |
| 4.Anti-Tau Ab | 9/9/8/6=32 | 9/7/8/8=32 | 8/8/8/5=29 | -- | | | | | | | | | | | |
| 5.Anti-Tau ASO | 9/8/6/5=28 | 9/7/6/7=29 | 8/8/6/4=26 | 8/7/6/7=28 | -- | | | | | | | | | | |
| 6.Intranasal Ins | 9/9/9/6=33 | 7/8/8/5=28 | 8/9/8/5=30 | 7/7/7/4=25 | 7/7/6/4=24 | -- | | | | | | | | | |
| 7.TREM2 Ag | 8/8/7/5=28 | 8/6/7/5=26 | 8/7/7/4=26 | 8/6/7/5=26 | 8/6/6/4=24 | 7/7/7/4=25 | -- | | | | | | | | |
| 8.FUS | 8/9/6/5=28 | 7/7/7/7=28 | 7/8/6/5=26 | 7/7/6/5=25 | 7/7/6/5=25 | 7/8/6/4=25 | 7/6/6/4=23 | -- | | | | | | | |
| 9.Mito | 9/9/8/5=31 | 7/7/7/4=25 | 8/8/7/5=28 | 7/7/6/4=24 | 7/7/6/4=24 | 8/8/7/4=27 | 7/7/6/4=24 | 6/7/5/4=22 | -- | | | | | | |
| 10.Anti-Infl | 8/9/8/5=30 | 6/6/7/5=24 | 8/8/7/5=28 | 7/6/6/4=23 | 7/6/6/4=23 | 7/7/7/4=25 | 7/6/6/4=23 | 7/6/5/4=22 | 8/8/7/5=28 | -- | | | | | |
| 11.Senolytic | 8/8/7/5=28 | 7/6/6/4=23 | 8/7/6/4=25 | 7/6/5/4=22 | 7/6/5/4=22 | 7/7/6/4=24 | 7/6/5/4=22 | 6/6/5/4=21 | 8/7/6/5=26 | 7/6/6/5=24 | -- | | | | |
| 12.HDAC | 8/8/6/4=26 | 6/6/6/4=22 | 7/7/6/4=24 | 7/6/5/4=22 | 7/6/5/4=22 | 7/7/6/4=24 | 7/6/5/4=22 | 6/6/5/4=21 | 7/7/6/4=24 | 7/6/6/4=23 | 7/6/5/4=22 | -- | | | |
| 13.σ1 Agonist | 8/8/7/4=27 | 6/7/6/4=23 | 7/7/6/4=24 | 6/6/5/4=21 | 6/6/5/4=21 | 7/7/6/4=24 | 6/6/5/4=21 | 6/6/5/4=21 | 7/7/6/4=24 | 7/6/6/4=23 | 6/6/5/4=21 | 6/6/5/4=21 | -- | | |
| 14.Glutamate | 7/8/6/4=25 | 6/6/6/4=22 | 7/7/6/4=24 | 6/5/5/4=20 | 6/5/5/4=20 | 7/7/6/4=24 | 6/5/5/4=20 | 6/5/5/4=20 | 6/6/5/4=21 | 6/5/5/4=20 | 6/5/5/4=20 | 6/5/5/4=20 | 6/5/5/4=20 | -- | |
| 15.Gene Tx | 7/6/4/4=21 | 6/5/4/5=20 | 6/5/4/4=19 | 6/5/4/5=20 | 6/5/4/5=20 | 6/5/4/4=19 | 6/5/4/4=19 | 5/5/4/4=18 | 6/5/4/4=19 | 6/5/4/4=19 | 5/5/4/4=18 | 5/5/4/4=18 | 5/5/4/4=18 | 5/5/4/4=18 | -- |
| Dimension | Score | Rationale |
|-----------|:-----:|-----------|
| Mechanistic Synergy | 10 | Lifestyle addresses upstream modifiable risk factors; anti-amyloid removes existing plaques -- fully complementary |
| Safety Compatibility | 10 | No drug-drug interaction; lifestyle interventions have zero adverse events |
| Delivery Compatibility | 10 | Lifestyle requires no delivery; anti-amyloid is IV infusion -- completely separate modalities |
| Evidence | 8 | FINGER trial shows lifestyle + standard of care; EVOKE/EVOKE+ ongoing for lecanemab[@Ngandu2015] |
Clinical Rationale: The FINGER trial demonstrated that multi-domain lifestyle intervention (diet, exercise, cognitive training, vascular monitoring) slows cognitive decline in at-risk elderly. Combining lifestyle with lecanemab could address both upstream modifiable risk factors and existing amyloid pathology. The mechanisms are entirely non-overlapping: lifestyle reduces risk through vascular, metabolic, and inflammatory pathways[@Aisen2023]; anti-amyloid antibodies remove amyloid plaques directly[@vanDyck2023].
| Dimension | Score | Rationale |
|-----------|:-----:|-----------|
| Mechanistic Synergy | 10 | Both address metabolic and inflammatory pathways from different angles |
| Safety Compatibility | 10 | Both extremely safe -- lifestyle has no drugs; GLP-1 has well-characterized safety profile |
| Delivery Compatibility | 10 | Lifestyle = behavioral; GLP-1 = weekly injection -- separate modalities |
| Evidence | 7 | FINGER trial for lifestyle; EVOKE/EVOKE+ trials for semaglutide in early AD[@Swanson2023]; no direct combo trials yet |
Clinical Rationale: Both GLP-1 agonists and multi-domain lifestyle interventions target metabolic dysfunction -- a key AD risk factor that accelerates amyloid accumulation and neuronal loss[@Lee2024]. GLP-1 receptors in the brain mediate anti-inflammatory and neuroprotective effects distinct from lifestyle's cardiovascular benefits. Maximum safety profile combined with complementary mechanisms. EVOKE is investigating semaglutide 14mg in early AD (NCT04777396)[@Swanson2023].
| Dimension | Score | Rationale |
|-----------|:-----:|-----------|
| Mechanistic Synergy | 9 | Insulin directly improves neuronal glucose metabolism; lifestyle improves overall systemic health |
| Safety Compatibility | 9 | Intranasal insulin has minimal systemic absorption; lifestyle is non-pharmacological |
| Delivery Compatibility | 9 | Intranasal = daily nasal spray; lifestyle = behavioral -- different administration routes |
| Evidence | 6 | SNIFF trials (SNIFF-1, SNIFF-2, SNIFF-3) show mixed results; no combination trials |
Clinical Rationale: [Intranasal insulin](/treatments/intranasal-insulin) directly improves brain glucose metabolism and modulates amyloid precursor protein processing, while lifestyle interventions address upstream cardiovascular and inflammatory risk factors[@Tariot2024]. The combination targets both central (insulin signaling) and peripheral (lifestyle) mechanisms of AD pathogenesis.
| Dimension | Score | Rationale |
|-----------|:-----:|-----------|
| Mechanistic Synergy | 8 | Anti-amyloid removes Aβ plaques; GLP-1 addresses neuroinflammation and metabolic dysfunction |
| Safety Compatibility | 9 | Both have good safety profiles; GLP-1 GI side effects not overlapping with ARIA risk |
| Delivery Compatibility | 9 | Both injectable (IV monthly + weekly subcutaneous) -- manageable coordination |
| Evidence | 7 | EVOKE/EVOKE+ trials ongoing for semaglutide in AD[@Swanson2023]; preclinical synergy demonstrated |
Clinical Rationale: [Lecanemab](/entities/lecanemab) removes plaques by binding soluble Aβ protofibrils[@vanDyck2023]; [GLP-1 agonists](/treatments/glp-1-agonists) reduce neuroinflammation through GLP-1 receptor signaling in microglia[@Lee2024]. These are mechanistically distinct pathways that may produce additive effects. Several trials are exploring combined amyloid reduction + metabolic protection strategies[@Cummings2024].
| Dimension | Score | Rationale |
|-----------|:-----:|-----------|
| Mechanistic Synergy | 9 | Aβ plaques vs tau tangles -- both extracellular, distinct pathological hallmarks |
| Safety Compatibility | 7 | Both can cause ARIA (amyloid-related imaging abnormalities); dual antibody approach increases ARIA risk |
| Delivery Compatibility | 8 | Both IV infusions -- could be coordinated on same day or alternating schedule |
| Evidence | 8 | Trials planning dual targeting; strong mechanistic rationale; recent anti-tau trials read out[@McDade2024] |
Clinical Rationale: The "dual attack" strategy -- simultaneously removing [Aβ plaques](/mechanisms/app-amyloid-pathway-alzheimers) and [tau tangles](/mechanisms/tau-phosphorylation-pathology-alzheimers)[@McDade2024]. Both are hallmarks of AD pathology and thought to act synergistically in a feedforward loop. Anti-amyloid reduces the upstream trigger; anti-tau addresses the downstream effector of neurodegeneration. Phase 2 combinations are being planned.
| Dimension | Score | Rationale |
|-----------|:-----:|-----------|
| Mechanistic Synergy | 9 | Both improve cellular energy metabolism from complementary angles |
| Safety Compatibility | 9 | Mitochondrial supplements (NAD+ boosters, urolithin A) have excellent safety; lifestyle adds no toxicity |
| Delivery Compatibility | 8 | Oral supplements + behavioral changes -- easy combination |
| Evidence | 5 | NAD+ boosters show promise in preclinical models; FINGER trial supports lifestyle |
Clinical Rationale: Mitochondrial dysfunction is a central feature of AD pathogenesis, with reduced complex I activity and altered mitophagy contributing to neuronal death[@Hampel2024]. NAD+ precursors (nicotinamide riboside, nicotinamide mononucleotide) restore cellular energetics; lifestyle (exercise, caloric restriction) independently improves mitochondrial biogenesis. The combination addresses bioenergetic failure from both pharmacological and behavioral angles.
| Dimension | Score | Rationale |
|-----------|:-----:|-----------|
| Mechanistic Synergy | 8 | Lifestyle reduces baseline inflammation; pharmacological anti-inflammatory adds targeted suppression |
| Safety Compatibility | 9 | Anti-inflammatory agents (masitinib, sargramostim) have manageable safety profiles |
| Delivery Compatibility | 8 | Oral/weekly injectable + behavioral -- straightforward |
| Evidence | 5 | Masitinib showed slowing on cognitive endpoints in Phase 3 (NCT02565511) |
Clinical Rationale: [Neuroinflammation](/mechanisms/neuroinflammation-alzheimers) is a key driver of AD progression. [Masitinib](/treatments/masitinib) targets mast cell-mediated neuroinflammation through CSF1R inhibition. Lifestyle interventions (Mediterranean diet, exercise) independently reduce systemic inflammatory markers (CRP, IL-6). The combination addresses neuroinflammation from both dietary/behavioral and pharmacological angles[@Cummings2024].
| Dimension | Score | Rationale |
|-----------|:-----:|-----------|
| Mechanistic Synergy | 7 | FUS enhances anti-Aβ antibody delivery through BBB opening; complementary delivery effect |
| Safety Compatibility | 7 | FUS carries small procedural risk; ARIA risk may be elevated with BBB opening |
| Delivery Compatibility | 7 | FUS is a procedural intervention; antibody is IV -- different settings |
| Evidence | 7 | Multiple trials combining FUS + lecanemab/donanemab in progress[@Cummings2024] |
Clinical Rationale: [Focused ultrasound](/treatments/focused-ultrasound-bbb-opening) with microbubble-mediated BBB opening can enhance delivery of [anti-amyloid antibodies](/treatments/lecanemab) to brain tissue, potentially increasing their efficacy. Early trials combining FUS with [Lecanemab](/entities/lecanemab) are underway. The synergy is primarily in enhanced drug delivery rather than complementary mechanism targeting.
| Dimension | Score | Rationale |
|-----------|:-----:|-----------|
| Mechanistic Synergy | 8 | GLP-1 improves insulin sensitivity and reduces neuroinflammation; mitochondrial boosters address bioenergetic failure directly |
| Safety Compatibility | 8 | Both are well-tolerated; GLP-1 has GI side effects that mitochondrial agents lack |
| Delivery Compatibility | 7 | Weekly GLP-1 injection + daily oral supplements -- easy |
| Evidence | 5 | Preclinical synergy demonstrated; no human combo trials |
Clinical Rationale: [GLP-1 receptor agonists](/treatments/glp-1-agonists) improve insulin signaling and reduce neuroinflammation[@Lee2024]; NAD+ boosters and mitophagy inducers address the bioenergetic crisis in AD neurons. The overlapping mechanisms (both targeting mitochondrial function and metabolic protection) may produce synergistic neuroprotective effects. Direct preclinical evidence supports this combination.
| Dimension | Score | Rationale |
|-----------|:-----:|-----------|
| Mechanistic Synergy | 8 | Anti-amyloid addresses upstream trigger; anti-inflammatory addresses downstream neuroinflammation triggered by Aβ |
| Safety Compatibility | 6 | Anti-inflammatory may theoretically reduce ARIA risk (inflammation component) but adds its own toxicity profile |
| Delivery Compatibility | 7 | Both injectable/infusion or oral -- can be coordinated |
| Evidence | 5 | Preclinical synergy demonstrated; masitinib trials ongoing[@Cummings2024] |
Clinical Rationale: [Amyloid plaques](/mechanisms/app-amyloid-pathway-alzheimers) trigger microglial activation and [neuroinflammation](/mechanisms/neuroinflammation-alzheimers)[@Cummings2024]. Removing plaques reduces the inflammatory trigger, but residual neuroinflammation may persist. Adding an anti-inflammatory agent (masitinib, sargramostim) could address this residual inflammatory burden. The mechanistic rationale is sound but direct clinical evidence is limited.
| Combination | Status | Trial Name | Phase |
|-------------|--------|-----------|-------|
| Lecanemab + lifestyle (FINGER protocol) | Planned | -- | Phase 4 |
| Semaglutide (GLP-1) in early AD | Recruiting | EVOKE, EVOKE+ | Phase 3 |
| Donanemab + anti-tau ASO | Planned | -- | Phase 2 |
| Lecanemab + FUS BBB opening | Active | -- | Phase 1/2 |
| Masitinib (anti-inflammatory) + standard of care | Completed | NCT02565511 | Phase 3 |
| Dasatinib + Quercetin (senolytic) in early AD | Recruiting | NCT04063124 | Phase 1/2 |
| Intranasal insulin + GLP-1 | Preclinical | -- | -- |
Related Hypotheses: